Triacsin C, a Fatty Acyl Coa Synthetase (FACS) Inhibitor, Improves Cardiac Performance Following Global Ischemia

Margaret Teresa Weis; Jasmine Tolson; Qian Chen; Lindon H. Young

doi:10.1096/fasebj.26.1_supplement.1136.18

Triacsin C, a Fatty Acyl Coa Synthetase (FACS) Inhibitor, Improves Cardiac Performance Following Global Ischemia

Margaret Teresa Weis, Jasmine Tolson, Qian Chen, Lindon H. Young

Department of Bio-Medical Sciences (PCOM)

Research output: Contribution to conference › Presentation

Abstract

Extensive evidence shows that eNOS is protective in ischemia/reperfusion (I/R) injury. We have shown that triacsin C, a (FACS) inhibitor, increases eNOS activity in the post-ischemic rat hind limb, suggesting that triacsin C might be useful in treatment of cardiac I/R. Isolated rat hearts, perfused at a constant pressure by the method of Langendorf, were subjected to a 30 minute period of global ischemia, followed by 45 minutes of reperfusion in the presence or absence of 5μM triacsin C.

At 45 minutes of reperfusion, LVDP and dP/dt in treated hearts were significantly better than in vehicle controls. Coronary flow and heart rate were not changed by treatment. The infarct area, visualized with 1% 2,3,5-triphenylterazolium, was significantly smaller in triacsin C treated hearts. The results support the hypothesis, and suggest that FACS inhibitors may represent a new category of drugs for I/R.

Original language	American English
DOIs	https://doi.org/10.1096/fasebj.26.1_supplement.1136.18
State	Published - Apr 2012
Event	Experimental Biology 2012 - Duration: Apr 1 2012 → …

Conference

Conference	Experimental Biology 2012
Period	4/1/12 → …

Disciplines

Medicine and Health Sciences
Cardiology

Access to Document

10.1096/fasebj.26.1_supplement.1136.18License: Unspecified

Cite this

@conference{206c699ffca54ccfa36fa388ea4902a2,

title = "Triacsin C, a Fatty Acyl Coa Synthetase (FACS) Inhibitor, Improves Cardiac Performance Following Global Ischemia",

abstract = " Extensive evidence shows that eNOS is protective in ischemia/reperfusion (I/R) injury. We have shown that triacsin C, a (FACS) inhibitor, increases eNOS activity in the post-ischemic rat hind limb, suggesting that triacsin C might be useful in treatment of cardiac I/R. Isolated rat hearts, perfused at a constant pressure by the method of Langendorf, were subjected to a 30 minute period of global ischemia, followed by 45 minutes of reperfusion in the presence or absence of 5μM triacsin C. At 45 minutes of reperfusion, LVDP and dP/dt in treated hearts were significantly better than in vehicle controls. Coronary flow and heart rate were not changed by treatment. The infarct area, visualized with 1% 2,3,5-triphenylterazolium, was significantly smaller in triacsin C treated hearts. The results support the hypothesis, and suggest that FACS inhibitors may represent a new category of drugs for I/R.",

author = "Weis, {Margaret Teresa} and Jasmine Tolson and Qian Chen and Young, {Lindon H.}",

year = "2012",

month = apr,

doi = "10.1096/fasebj.26.1_supplement.1136.18",

language = "American English",

note = "Experimental Biology 2012 ; Conference date: 01-04-2012",

}

TY - CONF

T1 - Triacsin C, a Fatty Acyl Coa Synthetase (FACS) Inhibitor, Improves Cardiac Performance Following Global Ischemia

AU - Weis, Margaret Teresa

AU - Tolson, Jasmine

AU - Chen, Qian

AU - Young, Lindon H.

PY - 2012/4

Y1 - 2012/4

N2 - Extensive evidence shows that eNOS is protective in ischemia/reperfusion (I/R) injury. We have shown that triacsin C, a (FACS) inhibitor, increases eNOS activity in the post-ischemic rat hind limb, suggesting that triacsin C might be useful in treatment of cardiac I/R. Isolated rat hearts, perfused at a constant pressure by the method of Langendorf, were subjected to a 30 minute period of global ischemia, followed by 45 minutes of reperfusion in the presence or absence of 5μM triacsin C. At 45 minutes of reperfusion, LVDP and dP/dt in treated hearts were significantly better than in vehicle controls. Coronary flow and heart rate were not changed by treatment. The infarct area, visualized with 1% 2,3,5-triphenylterazolium, was significantly smaller in triacsin C treated hearts. The results support the hypothesis, and suggest that FACS inhibitors may represent a new category of drugs for I/R.

AB - Extensive evidence shows that eNOS is protective in ischemia/reperfusion (I/R) injury. We have shown that triacsin C, a (FACS) inhibitor, increases eNOS activity in the post-ischemic rat hind limb, suggesting that triacsin C might be useful in treatment of cardiac I/R. Isolated rat hearts, perfused at a constant pressure by the method of Langendorf, were subjected to a 30 minute period of global ischemia, followed by 45 minutes of reperfusion in the presence or absence of 5μM triacsin C. At 45 minutes of reperfusion, LVDP and dP/dt in treated hearts were significantly better than in vehicle controls. Coronary flow and heart rate were not changed by treatment. The infarct area, visualized with 1% 2,3,5-triphenylterazolium, was significantly smaller in triacsin C treated hearts. The results support the hypothesis, and suggest that FACS inhibitors may represent a new category of drugs for I/R.

U2 - 10.1096/fasebj.26.1_supplement.1136.18

DO - 10.1096/fasebj.26.1_supplement.1136.18

M3 - Presentation

T2 - Experimental Biology 2012

Y2 - 1 April 2012

ER -